New guidance on the safety of medicine use in people with mitochondrial myopathies

Published Date
13/02/2020
Author
Louise Clarke
Category
Research

 

International Mitopatients Logo

 

After an international study, The IMP has released updated guidance on the medicines that should be avoided or used with caution in people with primary mitochondrial disease. The IMP is a network of mitochondrial disease patient organisations which MDUK is part of. The study, carried out by specialists, researchers and clinicians, was published in a scientific journal and there are now two lists for people with the conditions. These lists detail the medicines and procedures that should avoided or used with caution and the medicines that are considered safe.

Those with mitochondrial disease and their families may wish to share this list with their doctors to discuss what this may mean for them.

More information on why and how the list was updated can be found on the IMP website.

You can also find a Q&A on the list of medicines that should be used with caution.

If you have any research questions, please contact our Research Line on 02078034813 or research@musculardystrophyuk.org  

Keep in touch